



## Development of Biomarker-Driven Targeted Therapies in Cancers

Guest Editor:

**Dr. Anne Mary Noonan**

Department of Internal Medicine,  
Division of Medical Oncology, The  
Ohio State University  
Comprehensive Cancer Center,  
James Cancer Hospital and  
Solove Research Institute,  
Columbus, OH 43210, USA

Deadline for manuscript  
submissions:

**closed (10 February 2023)**

### Message from the Guest Editor

Dear Colleagues,

We are pleased to invite you to submit articles to our Special Edition entitled “Biomarker-Driven Targeted Therapies in Cancers”. Significant progress has been made in recent decades for certain cancer types where specific molecular alterations drive cancer progression. The development of imatinib targeting BCR-ABL, c-KIT, and PDGFRA revolutionized the treatment of chronic myeloid leukemia and GIST and paved the way for modern targeted therapies. As a result of biomarker-driven targeted therapies, the prognosis of malignancies such as HER-2 positive breast cancers and BRAF-mutated melanoma has improved greatly. However, elucidating signaling networks for many other malignancies has been more challenging, with constellations of signaling pathways often being involved, making the development of targeted therapies more difficult for certain tumors. Thus, a multi-pronged targeted approach may be needed with exploration of targets beyond those found by next-generation sequencing.

This Special Issue aims to describe current research surrounding the development of the next generation of biomarker-driven targeted therapies for cancer.

Dr. Anne Mary Noonan





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma